Drug details
Glyxambi (empagliflozin and linagliptin tablets)
type of Antidiabetics, SGLT2 Inhibitors, Antidiabetics, Dipeptyl Peptidase-IV Inhibitors
Glyxambi (empagliflozin and linagliptin) is a combination of an inhibitor of the sodium-glucose co-transporter (SGLT2) and an inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
This drug may have the following side effects:
- hives,
- difficulty breathing,
- rash,
- vomiting,
- diarrhea,
- lightheadedness,
- shortness of breath,
- confusion,
- dizziness,
- swelling,
- headache,
- sweating,
- weakness,
- unusual tiredness,
- drowsiness,
- severe stomach pain,
- rapid weight gain,
- swelling of the face, tongue or throat,
- irritability,
- shaking,
- hunger,
- joint pain, and
- severe dizziness,
- vaginal itching or discharge,
- rapid heartbeat,
- pain, tenderness, or swelling around your anus or genitals,
- blisters on the skin
The following drugs are related to Glyxambi, either as a replacement or used together:
- Actos (pioglitazone hydrochloride)
- Amaryl Tablets (glimepiride)
- Byetta (exenatide injection)
- Invokana (canagliflozin tablets)
- Diabinese (chlorpropamide)
- Zegalogue (dasiglucagon injection)
- NovoLog (insulin aspart [rdna origin] inj)
- NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin))
- Lantus (insulin glargine [rdna origin] injection)
- Janumet (sitagliptin metformin hcl)
- Janumet XR (sitagliptin and metformin hcl)
- Starlix Tablet (nateglinide)
- NovoLog Mix 50/50 (50% insulin aspart protamine suspension and 50% insulin aspart injection)
- Symlin (pramlintide acetate injection)